PT  - JOURNAL ARTICLE
AU  - Velu, P.
AU  - Craney, A.
AU  - Ruggiero, P.
AU  - Sipley, J.
AU  - Cong, L.
AU  - Hissong, Erika M.
AU  - Loda, M.
AU  - Westblade, L. F.
AU  - Cushing, M.
AU  - Rennert, H.
TI  - Rapid implementation of SARS-CoV-2 emergency use authorization RT-PCR testing and experience at an academic medical institution
AID  - 10.1101/2020.06.05.20109637
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.06.05.20109637
4099  - http://medrxiv.org/content/early/2020/06/08/2020.06.05.20109637.short
4100  - http://medrxiv.org/content/early/2020/06/08/2020.06.05.20109637.full
AB  - An epidemic caused by an outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in China in December 2019 has since rapidly spread internationally, requiring urgent response from the clinical diagnostics community. We present a detailed overview of the clinical validation and implementation of the first laboratory-developed real-time reverse-transcription-PCR (rRT-PCR) test offered in the NewYork-Presbyterian Hospital system following the emergency use authority (EUA) guidance issued by the US Food and Drug Administration. Validation was performed on nasopharyngeal and sputum specimens (n=124) using newly designed dual-target rRT-PCR (altona RealStar® SARS-CoV-2 Reagent) for detecting of SARS-CoV-2 in upper respiratory and lower respiratory tract specimens, including bronchoalveolar lavage and tracheal aspirates. Accuracy testing demonstrated excellent assay agreement between expected and observed values. The limit of detection (LOD) was 2.7 and 23.0 gene copies/reaction for nasopharyngeal and sputum specimens, respectively. Retrospective analysis of 1,694 tests from 1,571 patients revealed increased positivity in older patients and males compared to females, and an increasing positivity rate from approximately 20% at the start of testing to 50% at the end of testing three weeks later. Our findings demonstrate that the assay accurately and sensitively identifies SARS-CoV-2 in multiple specimen types in the clinical setting and summarizes clinical data from early in the epidemic in New York City.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNAFunding StatementNo external funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The IRB Committee at Weill Cornel Medicine (WCM) approved this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNA